4.80

3.00% 0.14

After Hours: 4.80

Aquestive Therapeutics Inc (AQST)

Overview News Price History Option Chain Financials Discussions Forecast

Aquestive Therapeutics Inc stock is traded at $4.80, with a volume of 2.61M. It is up +3.00% in the last 24 hours and up +30.43% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Previous Close:

$4.66

Open:

$4.67

24h Volume:

2.61M

Relative Volume:

1.07

Market Cap:

$602.46M

Revenue:

$50.27M

Net Income/Loss:

$-68.91M

P/E Ratio:

-7.9602

EPS:

-0.603

Net Cash Flow:

$-44.32M

1W Performance:

+11.89%

1M Performance:

+30.43%

6M Performance:

+17.36%

1Y Performance:

+20.60%

1-Day Range:

$4.56

$4.82

1-Week Range:

$4.25

$4.82

52-Week Range:

$2.93

$7.55

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name

Aquestive Therapeutics Inc

Sector

Healthcare (1033)

Industry

Drug Manufacturers - Specialty & Generic (79)

Phone

908-941-1900

Address

30 TECHNOLOGY DRIVE, WARREN, NJ

Employee

147

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

AQST's Discussions on Twitter

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AQST Aquestive Therapeutics Inc	4.80	564.17M	50.27M	-68.91M	-44.32M	-0.603
TAK Takeda Pharmaceutical Co Adr	18.24	57.90B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.16	43.41B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	36.93	42.89B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.17	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	512.88	22.35B	3.17B	1.29B	1.01B	27.09

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
May-10-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Piper Sandler	Overweight
Mar-28-24	Initiated	Raymond James	Outperform
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy
Aug-20-18	Initiated	JMP Securities	Mkt Outperform
Aug-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

Aug 21, 2026

Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat

Aug 21, 2026

Aug 20, 2026

Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks

Aug 20, 2026

Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat

Aug 20, 2026

Aug 19, 2026

Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Nigeria

Aug 19, 2026

Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat

Aug 19, 2026

Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha

Aug 19, 2026

Aug 18, 2026

Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com

Aug 18, 2026

Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media

Aug 18, 2026

Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet

Aug 18, 2026

Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget

Aug 18, 2026

Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan

Aug 18, 2026

Aquestive Therapeutics (AQST) 10K Form and Latest SEC Filings 2026 - MarketBeat

Aug 18, 2026

Aug 17, 2026

Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan

Aug 17, 2026

AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review

Aug 17, 2026

Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review

Aug 16, 2026

2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse

Aug 16, 2026

Aug 15, 2026

Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - MarketBeat

Aug 15, 2026

Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 13, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aug 13, 2026

LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Aug 13, 2026

Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat

Aug 13, 2026

Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm

Aug 13, 2026

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Aug 13, 2026

Aug 12, 2026